Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07029828 · ClinicalTrials.gov registry record · Phase 3
A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.
A Phase 3 study of Severe Alopecia Areata, sponsored by Pfizer.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 140
- Enrollment target
- 4
- Study locations
NCT07029828 is a Phase 3 study of Severe Alopecia Areata that is actively recruiting participants, run by Pfizer. The registered enrollment target is 140 participants. The trial reports 4 study locations across 4 states.
The verdict
NCT07029828, a Phase 3 study of Severe Alopecia Areata, is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 140 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this clinical trial is to learn about long-term safety and long-term effects of the study medicine (called ritlecitinib) for the potential treatment of severe alopecia areata, a condition that causes hair loss. This study is seeking participants who have: * previously completed one of Pfizer's pediatric studies for Alopecia Areata (B7981027 or B7981031). * at least 50% scalp hair loss due to alopecia areata (for participants enrolling from the study B7981031). * received varicella vaccination (2 doses) or have been infected by varicella zoster virus before based on blood test reports. All participants in this study will receive the study medicine (ritlecitinib). Participants who received ritlecitinib higher or lower doses in the parent Study B7981027 will continue receiving the same ritlecitinib dose in this trial. Participants who received placebo in the parent Study B7981027 and all participants from parent Study B7981031 will receive either higher or lower dose of ritlecitinib in this trial. The study medicine is a capsule that is taken by mouth. It is taken 1 time each day at home. The study will help see if ritlecitinib is safe and effective. Participants will take part in this study for a duration of up to 3 years (36 months). During this time, they will have 17 study visits at the study clinic. The study team will also call participants once a month over the phone.
Conditions Studied
Interventions
- DRUG Ritlecitinib higher dose
- DRUG Ritlecitinib lower dose
Study Locations (4)
Florida
- Pediatric Skin Research - Miami
Indiana
- Dawes Fretzin Clinical Research Group, LLC - Indianapolis
Oregon
- Northwest Dermatology Institute - Portland
Texas
- Texas Dermatology and Laser Specialists - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2025-09-10 |
| Est. Completion | 2030-06-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07029828
The ClinicalTrials.gov registry entry for NCT07029828 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Severe Alopecia Areata appearing as the primary indexed condition, and to 2 interventions - of which Ritlecitinib higher dose is the first listed.
NCT07029828 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Florida, Indiana, Oregon.
Frequently Asked Questions
What is clinical trial NCT07029828 about?
NCT07029828 is a clinical study titled "A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.". The purpose of this clinical trial is to learn about long-term safety and long-term effects of the study medicine (called ritlecitinib) for the potential treatment of severe alopecia areata, a condition that causes hair loss. This study is seeking participants who have: * previously completed one ...
What is the current status of trial NCT07029828?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 140 participants. The study started on 2025-09-10. Estimated completion is 2030-06-26.
What conditions does trial NCT07029828 study?
This clinical trial studies the following conditions: Severe Alopecia Areata.
What interventions are being tested in trial NCT07029828?
The interventions under investigation include: Ritlecitinib higher dose (DRUG), Ritlecitinib lower dose (DRUG).
Who is sponsoring clinical trial NCT07029828?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07029828 being conducted?
This trial has 4 study locations across Florida, Indiana, Oregon, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Severe Alopecia Areata
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.